Illumina (XSWX:ILMN) Forward Rate of Return (Yacktman) %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:ILMN Illumina Inc XSWX:ILMN
76 GF Score
Price CHF155.14
GF Value CHF107.32
! 7 Warning Signs
View Full Analysis

What is Illumina Forward Rate of Return (Yacktman) %?

Illumina XSWX:ILMN 76 Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2026. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF107.32. The stock has 7 warning signs investors should review. Among 90 Medical Diagnostics & Research companies, Illumina ranks worse than 65.56% on this metric.

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Illumina's forward rate of return for was 0.00%.

The historical rank and industry rank for Illumina's Forward Rate of Return (Yacktman) % or its related term are showing as below:

XSWX:ILMN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.55   Med: 20.07   Max: 22.2
Current: -2.27

During the past 13 years, Illumina's highest Forward Rate of Return was 22.20. The lowest was -2.55. And the median was 20.07.

XSWX:ILMN's Forward Rate of Return (Yacktman) % is ranked worse than
65.56% of 90 companies
in the Medical Diagnostics & Research industry
Industry Median: 5.07 vs XSWX:ILMN: -2.27

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Illumina  (XSWX:ILMN) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Illumina Forward Rate of Return (Yacktman) % Related Terms


Illumina Forward Rate of Return (Yacktman) % Historical Data

* Premium members only.

The historical data trend for Illumina's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Forward Rate of Return (Yacktman) % Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.98 0.00 0.00 0.00 0.00

Illumina Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSWX:ILMN vs MTD, DGX, LH: Forward Rate of Return (Yacktman) % Comparison

For the Diagnostics & Research subindustry, Illumina's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina Forward Rate of Return (Yacktman) % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Illumina's Forward Rate of Return (Yacktman) % falls into.


XSWX:ILMN
76GF Score
Illumina Inc XSWX:ILMN
Forward Rate of Return (Yacktman) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Illumina Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Illumina's Forward Rate of Return of Jun. 2026 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=4.36761905/143.38+-0.0666
=-3.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Rate of Return (Yacktman) % of 0.00% mean?
Illumina (XSWX:ILMN) has a Forward Rate of Return (Yacktman) % of 0.00% as of Jun. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Illumina and its competitors. According to the industry distribution chart, Illumina ranks #59 out of 90 companies in the Medical Diagnostics & Research industry, placing it in the top 65.6%.
Is Illumina's Forward Rate of Return (Yacktman) % too high?
Illumina's current Forward Rate of Return (Yacktman) % is 0.00%. Based on the distribution chart, Illumina ranks #59 out of 90 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Forward Rate of Return (Yacktman) % compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #59 out of 90 companies for Forward Rate of Return (Yacktman) %. This places Illumina in the lower half of its industry. The industry median Forward Rate of Return (Yacktman) % is 5.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Medical Diagnostics & Research company?
The median Forward Rate of Return (Yacktman) % among Medical Diagnostics & Research companies is 5.07, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median Forward Rate of Return (Yacktman) % is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Forward Rate of Return (Yacktman) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Forward Rate of Return (Yacktman) % of 0.00%. The stock's GF Value™ is CHF107.32, compared to a current price of CHF155.14 — trading 44.6% above its estimated fair value. The current Forward Rate of Return (Yacktman) % is 0.00%. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (XSWX:ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of CHF155.14 is trading 44.6% above its estimated GF Value™ of CHF107.32.

Key valuation signals for XSWX:ILMN:

  • Forward Rate of Return (Yacktman) %: 0.00%
  • GF Value™: CHF107.32 vs. price of CHF155.14 (44.6% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score

Get the complete analysis for XSWX:ILMN

Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF155.14
Price
CHF107.32
GF Value